SCHEMBL9891418

SCHEMBL9891418

CCC(N)(CO)COC(=O)OPF

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.31
S1PR3 Q99500 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10038484 0.77 S1PR1 (0.33) S1PR1S1PR3
SCHEMBL28232410 0.74 ALDH1A1 (0.41) S1PR1S1PR3
SCHEMBL14195294 0.70 MEN1 (0.32) S1PR1S1PR3
SCHEMBL22346341 0.70 MEN1 (0.32) S1PR1S1PR3
SCHEMBL12328700 0.68 CYP1A2 (0.38)
SCHEMBL13004398 0.65
SCHEMBL17067673 0.65 CYP4F2 (0.37) S1PR1S1PR3
SCHEMBL20865657 0.64 ALDH1A1 (0.46)
SCHEMBL1762048 0.64 LMNA (0.41)
SCHEMBL12191370 0.64 LMNA (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981151-B2 Perfluoropolyether urethane additives having (meth)acryl groups and hard coats 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-03-17 US disclosed
US-20140221689-A1 PERFLUOROPOLYETHER URETHANE ADDITIVES HAVING (METH)ACRYL GROUPS AND HARD COATS 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-08-07 US disclosed
US-8729211-B2 Perfluoropolyether urethane additives having (meth)acryl groups and hard coats 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-05-20 US disclosed
US-20130261280-A1 PERFLUOROPOLYETHER URETHANE ADDITIVES HAVING (METH)ACRYL GROUPS AND HARD COATS 3M INNOVATIVE PROPERTIES CO (US) 2013-10-03 US disclosed
US-8476398-B2 Perfluoropolyether urethane additives having (meth)acryl groups and hard coats 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-07-02 US disclosed
US-20120142883-A1 PERFLUOROPOLYETHER URETHANE ADDITIVES HAVING (METH)ACRYL GROUPS AND HARD COATS KLUN THOMAS P (US) 2012-06-07 US disclosed
US-8147966-B2 Perfluoropolyether urethane additives having (meth)acryl groups and hard coats 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-04-03 US disclosed
US-20100160595-A1 PERFLUOROPOLYETHER URETHANE ADDITIVES HAVING (METH)ACRYL GROUPS AND HARD COATS 3M INNOVATIVE PROPERTIES COMPANY 2010-06-24 US disclosed
US-7718264-B2 surface layer is a reaction product of a non-fluorinated crosslinking agent, and a perfluoropolyether urethane having a perfluoropolyether group and a terminal group having at least two (meth)acryl groups; suface modified silica particles 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-05-18 US disclosed
US-7332217-B2 Article and comprising fluorochemical surface layer 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-02-19 US disclosed
US-20070237948-A1 ARTICLE COMPRISING FLUOROCHEMICAL SURFACE LAYER 3M INNOVATIVE PROPERTIES COMPANY 2007-10-11 US disclosed
US-7267850-B2 Article comprising fluorochemical surface layer 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-09-11 US disclosed
US-20070014018-A1 Internal components of optical device comprising hardcoat 3M INNOVATIVE PROPERTIES COMPANY 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221689-A1 PERFLUOROPOLYETHER URETHANE ADDITIVES HAVING (METH)ACRYL GROUPS AND HARD COATS FUS, FLNA, ACR S1PR1 4419/4885S1PR3 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.